Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Ranbaxy Rejects Allegations
- Indian generic drug maker Ran- baxy Laboratories Ltd., which has its U.S. offices in Plainsboro, said last week it has agreed to produce specific documents sought by the U.S. Department of Justice in an investigation into alleged falsification of data relating to generic drugs. On July 3, the Justice Department...
- Research articles 2008-07-21
- On the Birla Bandwagon ; Why Ajay Srinivasan quit the global stage and headed home.
- On the Birla Bandwagon Why Ajay Srinivasan quit the global stage and headed home. By Anand AdhikariFew can boast a career graph that's been as meteoric and at the same time as unpredictable as that of Ajay Srinivasan. Close to a decade ago he took charge of Prudential Plc's Indian...
- Research articles 2007-12-30
- Pharma patent disputes out-of-court.
- Byline: Noemie Bisserbe Aug. 2--MUMBAI, India -- As litigation costs soar, several generic drug makers and innovative pharma companies are settling patent disputes out of court. In these settlements, the generic company usually agrees to delay its entrance in the market, in exchange for...
- Research articles 2007-08-02
- Ranbaxy-GSK to develop respiratory drug.
- Apr. 4--NEW DELHI -- Ranbaxy will develop a respiratory inflammation drug in collaboration GlaxoSmithKline GSK, as part of their new multi-year R&D agreement, a Ranbaxy release on Monday said. Ranbaxy could get up to $100 million in potential milestone payments for a product developed by it...
- Research articles 2007-04-04
- PPD deal worth $44 m for Ranbaxy.
- Mar. 10--BANGALORE, India -- The recent in-licensing deal between Indian pharma major Ranbaxy and PPD, a Nasdaq-listed contract research organisation CRO, could be worth up to $44 million for the Gurgaon-based company, the Wilmington, North Carolina-based CRO has said. In its form 8-K...
- Research articles 2007-03-10
- Ranbaxy gets US nod to mkt its drug.
- Feb. 1--NEW DELHI -- Gurgaon-based pharmaceutical major Ranbaxy Labs today announced that RLL has received approval from the US Food and Drug Administration to market Amoxicillin and Clavulanate Potassium for Oral Suspension. The Division of Bioequivalence has determined the Ranbaxy formulation to be bioequivalent and, therefore,...
- Research articles 2007-02-01
- US generics lures pharma cos again.
- Feb. 15--NEW DELHI -- Some good news may finally be round the corner for domestic pharma majors Ranbaxy and Dr Reddy's Laboratories, among others. They were hit hard by price erosion in the US generic market last year, but analysts now project an upward...
- Research articles 2006-02-15
- Dr Reddy's, Ranbaxy lead race for German co.
- Feb. 8--Only Ranbaxy and Dr Reddy's seem to be left in the race for the German generic company Betapharm Arzneimittel. According to banking sources, the two companies are in the lead and one of them is likely to clinch the deal. The industry buzz...
- Research articles 2006-02-08
- Ranbaxy in pact with Swiss company.
- Jan. 11--DELHI -- Ranbaxy on Tuesday announced a co-marketing agreement with Ferring International of Switzerland, a speciality biopharmaceutical company, for the latter's hormone tablet Desmopressin in India. Desmopressin, a structural analogue of the pituitary hormone Arginine Vasopressin, is used to treat Nocturia, a condition seen...
- Research articles 2006-01-11
- Passion to Win: How Winning Companies Develop and Sustain Competitive Edge
- Passion to Win: How Winning Companies Develop and Sustain Competitive Edge By Abad Ahmad and O P Chopra Excel Books Private Limited, New Delhi, 2004; Pages: 322; Price: Rs. 250; ISBN: 81-7446-389-5. This book is the product of the efforts of two Delhi University Professors, Abad Ahmad and O P...
- Research articles 2006-01-01
- Corporations rush products to aid tsunami victims.
- Jan. 1--NEW DELHI -- Adverse times call for drastic measures. On a normal day freightless cargo transport, free air trip on a private airline without an apex scheme, emergency cash advance on credit cards and the like might sound like consumer schemes or an example of an...
- Research articles 2005-01-01
- Indian company pulls cheap AIDS drugs from WHO listing amid test doubts
- GENEVA AFP — India's top pharmaceutical group Ranbaxy has withdrawn all its anti-AIDS drugs from World Health Organisation certification after it found the laboratory tests proving their effectiveness were deficient, the UN health agency said. The WHO listing sets minimum quality standards for cheaper medication and is a cornerstone...
- Research articles 2004-11-09
- Pfizer may push for settlement on Lipitor.
- Jun. 10--MUMBAI/DELHI -- In '03, Ranbaxy challenged the patent of the blockbuster drug in the US market, which is called a para IV filing. If Ranbaxy wins the case, it could ensure that the company's generic product has some period of exclusivity. Jun. 10--MUMBAI/DELHI...
- Research articles 2005-06-10
- Windfall for Indian firms after Clinton drugs deal, but patients must wait
- BOMBAY AFP ? Indian pharmaceutical companies are expecting huge growth after former US president Bill Clinton brokered a deal to slash the costs of their AIDS drugs in 13 countries, but activists are worried that Indian patients will not immediately benefit. Clinton in October announced an agreement with three...
- Research articles 2003-11-27
- Ranbaxy to Be Commended for Its Withdrawal of all WHO Prequalified HIV/AIDS Medicines, Says Hudson Institute
- WASHINGTON, Nov. 11 /U.S. Newswire/ -- On Nov. 9, the Indian drug company Ranbaxy announced the withdrawal of all seven of its HIV/ AIDS medicines from the World Health Organization WHO Prequalification system. Ranbaxy informed WHO of its decision afterWASHINGTON, Nov. 11 /U.S. Newswire/ -- On Nov. 9, the Indian...
- Research articles 2004-11-11
- High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 2011
- NEW YORK -- Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents...
- Research articles 2007-07-10
- Ranbaxy gets taste of Merck bestseller.
- May 3--NEW DELHI -- Ranbaxy and Israeli generic major Teva Pharmaceutical are likely to get a windfall by having six months without competition to sell their generic versions of Merck's blockbuster cholesterol drug Zocor. May 3--NEW DELHI -- Ranbaxy and Israeli generic major Teva...
- Research articles 2006-05-03
- AstraZeneca sues Ranbaxy over Nexium.
- Nov. 23--DELHI -- Ranbaxy has another high profile legal battle coming up, with AstraZeneca on Tuesday saying that it was suing the Indian drug major for challenging the patent of the latter's blockbuster anti-ulcer drug, Nexium. The legal battle wit Nov. 23--DELHI -- Ranbaxy has another...
- Research articles 2005-11-23
- Ranbaxy mixes bitter pill for Eli Lilly.
- Jan. 28--NEW DELHI -- In one of the high-profile patent disputes, multinational drug maker Eli Lilly's patent application for erectile dysfunction drug Cialis has been opposed by Ranbaxy at the pre-grant opposition stage. Jan. 28--NEW DELHI -- In one of the high-profile patent disputes,...
- Research articles 2006-01-28
- Will this bitter pill cost Ranbaxy dear?
- Dec. 18--NEW DELHI -- In a major setback to Ranbaxy, the US District Court of Delaware on Friday ruled against the company in its case for non-infringement and invalidation of two Pfizer patents on atorvastatin. Atorvastatin, a cholesterol-lowering d Dec. 18--NEW DELHI -- In a major...
- Research articles 2005-12-18
- << Previous
- page 1 of 2
- Next >>
Refining Tags
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
